Motif Bio (MTFB) has announced that the last patient has completed treatment in its 600 patient pivotal trial of iclaprim in ABSSSI (REVIVE-2). The achievement of this clinical milestone known as last patient out (LPO) follows on from a successful $25.8m fundraise achieved earlier in the year and brings iclaprim a step closer to potential commercialisation. We continue to expect top-line readout within two or three months, with clinical results for REVIVE-2 possibly being available as early a
09 Aug 2017
Last patient out….no time for doubt
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Last patient out….no time for doubt
- Published:
09 Aug 2017 -
Author:
Mark Brewer | Cavendish Research -
Pages:
8
Motif Bio (MTFB) has announced that the last patient has completed treatment in its 600 patient pivotal trial of iclaprim in ABSSSI (REVIVE-2). The achievement of this clinical milestone known as last patient out (LPO) follows on from a successful $25.8m fundraise achieved earlier in the year and brings iclaprim a step closer to potential commercialisation. We continue to expect top-line readout within two or three months, with clinical results for REVIVE-2 possibly being available as early a